These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18431028)

  • 1. Reduced expression of endogenous secretory receptor for advanced glycation endproducts in hippocampal neurons of Alzheimer's disease brains.
    Nozaki I; Watanabe T; Kawaguchi M; Akatsu H; Tsuneyama K; Yamamoto Y; Ohe K; Yonekura H; Yamada M; Yamamoto H
    Arch Histol Cytol; 2007 Dec; 70(5):279-90. PubMed ID: 18431028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease.
    Miller MC; Tavares R; Johanson CE; Hovanesian V; Donahue JE; Gonzalez L; Silverberg GD; Stopa EG
    Brain Res; 2008 Sep; 1230():273-80. PubMed ID: 18657529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease.
    Sasaki N; Toki S; Chowei H; Saito T; Nakano N; Hayashi Y; Takeuchi M; Makita Z
    Brain Res; 2001 Jan; 888(2):256-262. PubMed ID: 11150482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of RAGE splicing by hnRNP A1 and Tra2β-1 and its potential role in AD pathogenesis.
    Liu XY; Li HL; Su JB; Ding FH; Zhao JJ; Chai F; Li YX; Cui SC; Sun FY; Wu ZY; Xu P; Chen XH
    J Neurochem; 2015 Apr; 133(2):187-98. PubMed ID: 25689357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism.
    Lue LF; Walker DG; Brachova L; Beach TG; Rogers J; Schmidt AM; Stern DM; Yan SD
    Exp Neurol; 2001 Sep; 171(1):29-45. PubMed ID: 11520119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer's disease.
    Choi BR; Cho WH; Kim J; Lee HJ; Chung C; Jeon WK; Han JS
    Exp Mol Med; 2014 Feb; 46(2):e75. PubMed ID: 24503708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease.
    Lue LF; Yan SD; Stern DM; Walker DG
    Curr Drug Targets CNS Neurol Disord; 2005 Jun; 4(3):249-66. PubMed ID: 15975028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease.
    Leclerc E; Sturchler E; Vetter SW; Heizmann CW
    Rev Neurosci; 2009; 20(2):95-110. PubMed ID: 19774788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?
    Yan SD; Bierhaus A; Nawroth PP; Stern DM
    J Alzheimers Dis; 2009; 16(4):833-43. PubMed ID: 19387116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidative stress in Alzheimer's disease hippocampus: a topographical study.
    Cruz-Sánchez FF; Gironès X; Ortega A; Alameda F; Lafuente JV
    J Neurol Sci; 2010 Dec; 299(1-2):163-7. PubMed ID: 20863531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer's disease.
    Wang MY; Ross-Cisneros FN; Aggarwal D; Liang CY; Sadun AA
    Acta Neuropathol; 2009 Sep; 118(3):381-9. PubMed ID: 19277685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease.
    Yan SS; Chen D; Yan S; Guo L; Du H; Chen JX
    Front Biosci (Schol Ed); 2012 Jan; 4(1):240-50. PubMed ID: 22202057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous secretory receptor for advanced glycation end-products inhibits amyloid-β1-42 uptake into mouse brain.
    Sugihara T; Munesue S; Yamamoto Y; Sakurai S; Akhter N; Kitamura Y; Shiba K; Watanabe T; Yonekura H; Hayashi Y; Hamada J; Yamamoto H
    J Alzheimers Dis; 2012; 28(3):709-20. PubMed ID: 22064071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease.
    Donahue JE; Flaherty SL; Johanson CE; Duncan JA; Silverberg GD; Miller MC; Tavares R; Yang W; Wu Q; Sabo E; Hovanesian V; Stopa EG
    Acta Neuropathol; 2006 Oct; 112(4):405-15. PubMed ID: 16865397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease.
    Chen X; Walker DG; Schmidt AM; Arancio O; Lue LF; Yan SD
    Curr Mol Med; 2007 Dec; 7(8):735-42. PubMed ID: 18331231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.
    Srikanth V; Maczurek A; Phan T; Steele M; Westcott B; Juskiw D; Münch G
    Neurobiol Aging; 2011 May; 32(5):763-77. PubMed ID: 19464758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease.
    Takeuchi M; Yamagishi S
    Curr Pharm Des; 2008; 14(10):973-8. PubMed ID: 18473848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma.
    Takeuchi A; Yamamoto Y; Tsuneyama K; Cheng C; Yonekura H; Watanabe T; Shimizu K; Tomita K; Yamamoto H; Tsuchiya H
    Cancer; 2007 Jun; 109(12):2532-40. PubMed ID: 17497647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs.
    Cheng C; Tsuneyama K; Kominami R; Shinohara H; Sakurai S; Yonekura H; Watanabe T; Takano Y; Yamamoto H; Yamamoto Y
    Mod Pathol; 2005 Oct; 18(10):1385-96. PubMed ID: 15933755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease.
    Walker D; Lue LF; Paul G; Patel A; Sabbagh MN
    Expert Opin Investig Drugs; 2015 Mar; 24(3):393-9. PubMed ID: 25586103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.